Retatrutide (LY3437943) is Eli Lilly's investigational triple-agonist peptide — a single molecule that simultaneously activates the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This three-receptor approach distinguishes it from semaglutide (GLP-1 only) and tirzepatide (GLP-1/GIP dual agonist). In the Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023), the 12 mg dose produced a mean body weight reduction of approximately 24.2% at 48 weeks — the largest weight loss achieved by any obesity pharmacotherapy in a controlled trial at that time. Retatrutide is not yet FDA-approved and remains under investigation in Phase 3 trials.

Triple-agonist mechanism

Understanding why three receptors matters requires understanding what each one contributes.

GLP-1 receptor agonism is the foundation shared with semaglutide and tirzepatide. GLP-1 activation suppresses appetite through hypothalamic signaling, slows gastric emptying (increasing satiety per meal), and enhances glucose-dependent insulin secretion. This is the primary driver of reduced caloric intake.

GIP receptor agonism is shared with tirzepatide but absent from semaglutide. GIP acts on adipose tissue to improve lipid handling and insulin sensitivity. In the context of incretin therapy, GIP co-agonism appears to improve gastrointestinal tolerability — patients on dual and triple agonists generally experience somewhat less severe nausea than those on equi-effective doses of GLP-1-only agents, possibly because GIP partially counteracts GLP-1-mediated nausea through central mechanisms.

Glucagon receptor agonism is the unique differentiator. Glucagon stimulates hepatic lipid oxidation, increases energy expenditure through thermogenic pathways, and mobilizes fat stores directly. In isolation, glucagon raises blood glucose — but when combined with the insulin-secreting effects of GLP-1 and GIP agonism, the hyperglycemic effect is offset while the metabolic benefits (fat oxidation, energy expenditure) are preserved. This component is what theoretically pushes retatrutide beyond the weight loss ceiling of dual agonists: it adds an energy expenditure side to the equation rather than relying entirely on appetite suppression.

Dose selection

The Phase 2 trial tested four maintenance doses: 1 mg, 4 mg, 8 mg, and 12 mg administered once weekly by subcutaneous injection. Weight loss results at 48 weeks were dose-dependent:

1 mg: approximately 8.7% body weight loss
4 mg: approximately 17.1% body weight loss
8 mg: approximately 22.8% body weight loss
12 mg: approximately 24.2% body weight loss

The 12 mg dose showed the greatest efficacy. The incremental benefit from 8 mg to 12 mg was modest (roughly 1.4 percentage points additional weight loss), suggesting that 8 mg may represent a reasonable target for patients who experience dose-limiting side effects at 12 mg.

Titration schedule

The Phase 2 trial used a fixed titration schedule. A clinical protocol based on that approach:

Month 1 (Weeks 1-4): 2 mg subcutaneous once weekly. This starting dose establishes GI tolerance and allows assessment of individual sensitivity. Some patients experience nausea and reduced appetite even at this dose.

Month 2 (Weeks 5-8): 4 mg subcutaneous once weekly. First meaningful dose escalation. GI side effects typically peak during escalation steps and attenuate over 1-2 weeks at each stable dose.

Month 3 (Weeks 9-12): 8 mg subcutaneous once weekly. Significant appetite suppression is expected at this dose. Most patients report that the majority of their weight loss trajectory is established by this point.

Month 4 onward (Week 13+): 12 mg subcutaneous once weekly. Target maintenance dose. If GI side effects are intolerable, holding at 8 mg is a reasonable alternative given the modest incremental efficacy of the final dose step.

Slower titration option: For patients with poor GI tolerance or a history of severe nausea on GLP-1 agonists, extending each titration step to 6 weeks instead of 4 provides more time for adaptation. There is no clinical penalty for slower titration — it simply delays the timeline to full dose.

Side effects and management

The side effect profile of retatrutide is dominated by gastrointestinal effects, consistent with the incretin drug class:

Nausea: The most common side effect (reported in approximately 25-45% of patients across doses in Phase 2). Typically most severe during dose escalation steps. Management: eat smaller, more frequent meals; avoid high-fat foods during escalation; ginger or ondansetron as needed.
Diarrhea: More prevalent than with semaglutide, potentially related to the glucagon component's effects on GI motility. Usually transient.
Vomiting: Reported in 10-15% of patients at higher doses. If persistent, hold at current dose for an additional 2-4 weeks before re-attempting escalation.
Decreased appetite: This is the intended pharmacological effect rather than a true side effect, but extreme appetite suppression at higher doses can lead to inadequate protein and micronutrient intake if not managed deliberately.
Hepatic transaminase elevations: ALT and AST increases were observed in a small percentage of Phase 2 participants. The glucagon component stimulates hepatic metabolism, which may explain this. Most elevations were mild (less than 3 times the upper limit of normal) and resolved without intervention. This finding makes liver enzyme monitoring mandatory.

Monitoring

Monitoring should be more comprehensive than for GLP-1-only agents due to the glucagon component:

Weight and waist circumference: Biweekly during titration, monthly at maintenance. Body composition assessment (DEXA) at baseline and 6 months is ideal but not mandatory.
HbA1c and fasting glucose: Baseline, 3 months, and 6 months. The triple-agonist mechanism has strong glycemic effects even in non-diabetic individuals.
Lipid panel: Baseline and 3 months. Retatrutide showed significant improvements in triglycerides and LDL in Phase 2 data.
Liver enzymes (ALT, AST, GGT): Baseline, monthly during titration, then every 3 months. This is non-negotiable given the transaminase signal in Phase 2.
Renal function (BUN, creatinine): Baseline and 3 months. All incretin agents carry a theoretical risk of acute kidney injury from dehydration secondary to GI side effects.
Heart rate: GLP-1 agonists as a class increase resting heart rate by 2-4 bpm. Monitor at each visit.

Muscle preservation strategies

Rapid weight loss from any pharmacotherapy results in lean mass loss alongside fat loss. Clinical data on GLP-1 agonists suggest approximately 25-40% of weight lost is lean mass without countermeasures. For retatrutide, the glucagon component theoretically favors fat oxidation over protein catabolism, but this has not been confirmed in body composition sub-studies.

Practical strategies to minimize muscle loss:

Protein intake: Target 1.2-1.6 g/kg of ideal body weight daily. This is challenging at higher retatrutide doses where appetite is profoundly suppressed. Protein supplementation (whey, casein, or plant-based isolates) may be necessary to meet targets when whole-food intake is limited.
Resistance training: 2-4 sessions per week with progressive overload. This is the single most effective intervention for lean mass preservation during pharmacological weight loss. Patients should be encouraged to prioritize strength training over cardiovascular exercise during the weight loss phase.
Adequate total caloric intake: Ensure that caloric intake does not fall below approximately 1,200 kcal/day for women or 1,500 kcal/day for men, even when appetite is minimal. Severe caloric restriction combined with pharmacological appetite suppression accelerates muscle loss disproportionately.

Comparison with alternatives

Versus semaglutide (Wegovy): Semaglutide achieves approximately 15-17% weight loss at its maximum dose. Retatrutide's 24% at 12 mg represents a roughly 7-9 percentage point improvement. The addition of glucagon agonism provides an energy expenditure mechanism absent from semaglutide.

Versus tirzepatide (Zepbound): Tirzepatide achieves approximately 20-22% weight loss at its maximum dose. Retatrutide's incremental advantage over tirzepatide is smaller (2-4 percentage points) and attributable to the glucagon receptor component. Whether this increment justifies a newer, less-studied agent is a clinical judgment.

Evidence assessment

Retatrutide's evidence base is promising but early. The Phase 2 trial (n=338, 48 weeks) was well-designed, placebo-controlled, and produced striking results. However, Phase 2 data is insufficient for definitive conclusions about long-term safety, cardiovascular outcomes, or durability of weight loss. Phase 3 trials are underway with larger populations and longer follow-up periods. The compound is not FDA-approved, not commercially available through standard pharmaceutical channels, and should be considered investigational. Individuals using retatrutide outside of clinical trials are doing so without the safety infrastructure of regulated drug development, and should approach it with appropriate caution and medical supervision.